Physician profile
Jasrup Kaur
NPI 1154635423
$4,853.74
in general payments reported to CMS, 2019-2025
28 companies · $310 in 2025
The $310 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $632 · 2020: $942 · 2021: $401 · 2022: $980 · 2023: $962 · 2024: $628 · 2025: $310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,899.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,899.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,520.63 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $905.24 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $296.62 | 2019-2024 | Breztri, Fasenra |
| Pfizer INC. | $296.27 | 2019-2025 | |
| Abbott Laboratories | $274.93 | 2022-2023 | Freestyle Libre 3 |
| Amgen INC. | $230.64 | 2019-2025 | Krystexxa, Repatha, Otezla |
| Lilly USA, LLC | $217.51 | 2019-2023 | Mounjaro |
| Glaxosmithkline, LLC. | $213.20 | 2020-2025 | Shingrix |
| Merck Sharp & Dohme LLC | $156.31 | 2019-2021 | |
| Currax Pharmaceuticals LLC | $122.46 | 2019-2025 | Contrave, Onzetra Xsail |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.41 | 2019-2023 | Jardiance |
| Biohaven Pharmaceutical Holding Company Ltd. | $81.72 | 2022 | |
| Eisai INC. | $58.91 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $57.42 | 2019-2022 | |
| Boston Scientific Corporation | $51.32 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $42.23 | 2019 | |
| Upsher-Smith Laboratories LLC | $33.60 | 2020-2021 | |
| Exact Sciences Corporation | $28.64 | 2023-2024 | Cologuard Collection Kit |
| Genentech USA, INC. | $26.04 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.49 | 2022 | |
| Astellas Pharma US INC | $20.09 | 2024 | |
| Allergan, INC. | $14.62 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $14.48 | 2023 | Eliquis |
| Biohaven Pharmaceuticals, INC. | $13.44 | 2021 | |
| Adlon Therapeutics L.P. | $12.27 | 2020 | |
| Novartis Pharmaceuticals Corporation | $12.14 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $11.63 | 2019 | |
| Sanofi Pasteur INC. | $11.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasrup Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.